Cardiovascular and immunology products
Merck & Co.’s (MRK) cardiovascular products portfolio includes four drugs: Atozet, Adempas, Zetia, and Vytorin. Its immunology products include Simponi and Remicade.
The above chart compares the revenues for key products from Merck’s immunology and cardiovascular portfolio for the last eight quarters.
In Merck’s cardiovascular product portfolio, Adempas reported revenues of $70 million in 3Q17 compared to $48 million in 3Q16. Atozet reported revenues of $59 million in 3Q17 compared to $39 million in 3Q16.
Zetia and Vytorin are used to lower LDL (low-density lipoprotein) cholesterol levels. They decreased ~52% in operating revenues to $462 million in 3Q17 compared to $944 million in 3Q16.
Merck’s immunology product portfolio includes Remicade and Simponi.
Merck holds the marketing rights for Remicade only in European markets. Johnson & Johnson (JNJ) holds marketing rights for Remicade for major countries outside Europe. Remicade reported a decline of 31% in revenues to $214 million in 3Q17 compared to $311 million in 3Q16, driven by lower sales of Remicade due to competition from generic products and biosimilars. Revenues are expected to decline further as patients shift more to biosimilars.
Simponi reported 13% growth in revenues to $219 million in 3Q17 compared to $193 million in 3Q16.